COMPANIES IN FOCUSIn reports and research lists
RESEARCH BRIEFREPORT

Turkey explains how companies can buy their shares back from funds in liquidation

A Gen İlaç filing shows how the closing-price rule worked in an off-exchange purchase of nearly two million shares.

Share this report
Archive photograph of the Istanbul Stock Exchange building, 4 June 2007.
Archive photograph of the Istanbul Stock Exchange building, 4 June 2007. — Thomas Steiner · CC BY-SA 2.5

The record

When a Turkish investment fund in extraordinary liquidation holds a large stake in a listed company, selling the whole position on the exchange can push down the price the fund receives. On 15 November, Turkey’s Capital Markets Board (SPK) set out how liquidators can instead sell shares back to the company that issued them. The benchmark is the exchange closing price on the last trading day. [1]

A disclosure by pharmaceutical company Gen İlaç shows the rule in practice. On 12 November it bought back 1,975,000 of its own shares from funds whose liquidation was being handled by Türkiye İş Bankası. The price was TRY 4.61 per share, the closing price on Borsa İstanbul that day. The figures give a purchase price of TRY 9,104,750, about $180,800. Gen İlaç said the shares were transferred off-exchange and the funds in question no longer held any of its stock. [2] [3]

The regulator’s explanation turns on how many buyers are available at the quoted price. When a fund must sell more shares than buyers are willing to take at that price, part of its holding may fetch less. The board said using an observable closing price was intended to limit that effect and protect fund investors. Its statement did not disclose the combined value of the buybacks. [1]

The broader liquidation has produced two other figures. On 14 November, Vice President Cevdet Yılmaz said TRY 161 billion had been paid to 444,987 individual investors and voluntary repayments had reached TRY 33.4 billion. Those figures track investor payments and money returned. The Gen İlaç filing records what one issuer paid for its own shares. Neither the filing nor the board’s statement alleges misconduct by Gen İlaç or Türkiye İş Bankası. [4] [2]

Based on reporting from: SPK · 15.11.2026; Gen İlaç · KAP; Banca d’Italia · 13.11.2026; TRT Haber · 14.11.2026.

Source documents

04
  1. SPK · 15.11.2026spk.gov.tr
  2. Gen İlaç · KAPkap.org.tr
  3. Banca d’Italia · 13.11.2026bancaditalia.it
  4. TRT Haber · 14.11.2026trthaber.com

File updates

  1. First published

    Report published

Editorial note

The publications used in this account are listed above.

Submit a response or correction
Share this report
THE LEDGERS / COMMUNITY

Reader comments

Verified members can comment. Comments appear after editorial approval. Please address the evidence and avoid personal information.

No published comments yet.

Sign in / Create account →
Red and black print portrait of Abdulrahman El-Sayed, based on a still from the seriesMichigan, USA

The Ledgers Series

New documentary8 episodes

His Name Is Abdulrahman

What drew a doctor into Michigan politics?

Watch the series